Expert Interviews

Allergist and bestselling author Zachary Rubin, MD, joins host Renata Block, DMSc, MMS, PA-C, to debunk common allergy and atopic dermatitis myths and explore the immunology of the atopic march, cross-specialty collaboration, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

Many participants in the mobile screening program have never previously seen a dermatologist.

Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.

GLP-1 agonists may aid psoriasis, wound healing, and cardiometabolic health—Daniel Walker, MD, FAAD, explains why dermatologists should start to pay attention.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

April Armstrong, MD, MPH, discusses the role of itch as a key driver of psoriasis burden and shows how next-generation oral TYK2 inhibitors like envudeucitinib provide rapid symptom relief and meaningful improvements in quality of life.

April Armstrong, MD, MPH, highlights envudeucitinib as a next-generation oral TYK2 inhibitor that delivers biologic-level efficacy and strong safety, expanding treatment options for patients with moderate to severe psoriasis.

April Armstrong, MD, MPH, reframes psoriasis as a systemic inflammatory disease and highlights a shift toward earlier systemic treatment, with emerging oral therapies like TYK2 inhibitors offering improved efficacy and safety.

Kristen Lo Sicco, MD, shares why scarring alopecia can’t wait as LPP demands early treatment to prevent permanent hair loss amid limited FDA-approved options.

GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.

Discover how HS clinicians track real-life progress, set 3–4 month treatment goals, and build trust with patient-centered questions and empathy.

Dermatologists are exploring GLP-1 drugs for psoriasis and HS, but evidence is early—weight-loss benefits may help as add-ons, not replacements.

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

At AAD 2026, Lauren Madigan, MD, presented long-term PIONEER trial extension data and urged clinicians to sharpen their recognition of 2 clonally driven inflammatory diseases: indolent systemic mastocytosis and VEXAS syndrome.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss phase 3 data presented at AAD showing patients moving from very severe disease at baseline to absent or mild disease by week 40.

At AAD 2026, Diego Ruiz Dasilva, MD, makes the case that the black box warning on JAK inhibitors shouldn't deter appropriate prescribing.

The inaugural DermVIP Summit will be held from May 8 to 9 at the New York Academy of Medicine.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

Steven Daveluy, MD, reviews long-term trial data for bimekizumab in psoriasis and hidradenitis suppurativa presented at the 2026 AAD Annual Meeting.

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

New HS therapies emerge as JAK inhibitors show trial promise, safer long‑term data, and combo strategies expand options for severe and teen patients.

Why hidradenitis suppurativa patients go undertreated—fatigue, clinician risk fears, and insurance hurdles—plus tips to access modern biologics.

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

At AAD 2026, Andrew Blauvelt, MD, presented robust PASI responses and favorable safety from ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation TYK2 inhibitor.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.